Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure biospecimens (human biofluids, tissues, and cells). The company operates as a single reporting segment focused on the biospecimen industry.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $713,135 | $1,770,645 | N/A |
| Net Loss | $(1,047,243) | $(2,705,639) | N/A |
| Loss Per Share (Basic & Diluted) | $(0.42) | $(1.12) | N/A |
| Operating Cash Flow | N/A | $(1,288,079) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $588,775 |
| Total Assets | N/A | N/A | $6,034,501 |
| Total Liabilities | N/A | N/A | $5,412,528 |
| Working Capital | N/A | N/A | $(4,005,455) |
| Stockholders' Equity | N/A | N/A | $621,973 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 75% ($2.15M) for the three months ended June 30, 2025, compared to the same period in 2024. For the six months, revenue decreased 66% ($3.38M). This is primarily attributed to a 57% decrease in specimen count and a change in revenue recognition policy in Q4 2024 (shifting from recognizing revenue upon accession to recognizing upon delivery).
- Expense Reduction: Total operating expenses decreased 50% ($2.47M) for the quarter and 49% ($5.11M) for the six months. Significant reductions were seen in Sales and Marketing (down 76% for the quarter) and Technology (down 41% for the quarter) due to workforce reductions and decreased capitalization of software development costs.
- Net Loss Improvement: Despite lower revenue, the net loss decreased 50% for the quarter and 46% for the six months compared to the prior year periods, driven by aggressive cost-cutting measures.
- Liquidity Deterioration: Cash and cash equivalents declined from $1.88M at year-end 2024 to $589K at June 30, 2025. Working capital deficit widened to approximately $4.0M.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
The filing explicitly states that conditions raise substantial doubt regarding the Company's ability to continue as a going concern for one year from the date of issuance. The Company has an accumulated deficit of $74.6M and negative working capital. Management's plan to mitigate this includes generating additional revenue, deferring projects, and eliminating expenses, but success is not assured.
Legal Proceedings and Contingencies
- Focus Technology Solutions: A dispute regarding non-payment of IT services ($489,572 claimed) led to a temporary shutdown of the iSpecimen Marketplace in January/February 2025. A settlement of $500,000 was agreed upon, but the vendor failed to fully restore the platform. The Company is withholding payments and asserting counterclaims. The Court has ordered the Company to deposit 15% of revenue into a dedicated account up to $420,000 as pre-judgment security.
- Sales Tax Liability: The Company identified a historical sales tax liability. As of June 30, 2025, the estimated liability is approximately $273,000 plus $69,000 in interest and penalties. The Company is actively collecting from non-exempt customers and filing Voluntary Disclosure Agreements (VDAs).
- Other Litigation: Pending claims from Azenta ($651,262) and EGS ($425,684) regarding breach of contract. The Company intends to vigorously defend these claims.
Subsequent Events (Post-June 30, 2025)
- Public Offering: Closed July 25, 2025, raising approximately $4.0M gross proceeds via common stock and pre-funded warrants.
- Private Placement: Closed August 4, 2025, raising approximately $1.75M gross proceeds.
Internal Controls
Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to a material weakness regarding the design and maintenance of controls for sales tax calculation, collection, and remittance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $589K cash balance against the $4.0M working capital deficit and ongoing burn rate.
- Capital Raise Execution: Confirm the net proceeds and terms of the July and August 2025 equity offerings to assess immediate liquidity relief.
- Legal Exposure: Monitor the status of the Focus Technology settlement, specifically the requirement to deposit 15% of revenue and the outcome of counterclaims.
- Sales Tax Resolution: Track the reduction of the $273K sales tax liability and the effectiveness of the new tax software implementation.
- Revenue Recognition: Understand the impact of the Q4 2024 policy change (accession vs. delivery) on year-over-year comparability.
- Going Concern Status: Evaluate the probability of the Company meeting its obligations without further dilution or debt financing.